Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
Avalyn Pharma
Apr 30, 2026

Channel-specific outreach playbooks for deal origination.
Comparison posts, methodology, and analysis from the Tentt team.
Monthly market reports on M&A and private equity activity.
Free calculators for M&A, lending, and deal analysis.
Origination in the Age of AI.
CareDx has acquired Naveris, a diagnostics imaging business in New York, for $260 million. Naveris provides diagnostic imaging capabilities used in clinical workflows, supporting oncology-focused testing and patient management. CareDx acquisitions aim to expand healthcare diagnostics offerings and strengthen its presence in NY acquisitions for advanced laboratory and imaging-related services. The CareDx acquisition is a strategic acquisition under healthcare M&A, valued at up to $260 million and announced as an acquisition acquisition.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Avalyn Pharma
Apr 30, 2026
Avalyn Pharma
Apr 30, 2026
Parexel→Vitrana
Apr 29, 2026
Chiesi Group→KalVista Pharmaceuticals
Apr 29, 2026
CareDx→Naveris
Apr 29, 2026